InVision Medical Technology Corporation (“InVision”), a medical AI company backed by YCombinator, today announced that the American Medical Association (AMA) has adopted of new Category III Current Procedural Terminology (CPT) code for InVision Precision Cardiac Amyloid, analysis derived from augmentative analysis of an echocardiogram. The new CPT code, 0932T, is suited for adjunctive technologies assisting clinicians in assessing patients to provide a diagnostic heart failure subtype classification such as cardiac amyloidosis. The is a crucial step in the broader recognition and detection of cardiac amyloidosis.
Cardiac amyloidosis is a life-threatening, rare, underdiagnosed disease with available targeted treatments that require accurate subtype classification. Unfortunately, cardiac amyloidosis is often misdiagnosed or underdiagnosed, given the overlap of symptoms with other etiologies of heart failure with preserved ejection fraction. The novel technology is designed to address the unmet need for earlier diagnosis of amyloidosis patients, which otherwise may go unnoticed until the disease has advanced, delaying treatment, and adversely impacting patient outcomes. InVision Precision Cardiac Amyloid uses AI to detect cardiac amyloidoisis with evaluation of a full transthoracic echocardiogram containing apical-4-chamber and parasternal-long-axis view videos. The AI algorithm has undergone peer review and was published in JAMA Cardiology in 20221.
“Accurate assessment of heart function and disease etiology is critical for the diagnosis and treatment of heart failure. By offering advanced capabilities to assess heart function and subtype, we hope such technology can improve clinical care in critical junctures in a wide range of disease settings,” said Dr. Bryan He, PhD, co-founder of InVision. “Excellent clinical care should be available to every patient and hope to make such technologies available to all clinicians in all clinical settings.”
Last year, InVision previously announced it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its AI algorithm for echocardiography designed to aid in the early identification of cardiac amyloidosis. “Echocardiography is a key early exam in the cardiovascular care pathway, with unique potential for early disease identification. AI has the potential to improve access to care and may allow for timely detection of cardiac amyloidosis.” said Dr. David Ouyang, MD, Co-founder of InVision. “Our Breakthrough designation device for amyloidosis screening complements InVision Precision LVEF, our FDA cleared device for automated evaluation of cardiac function, and its usage can be tracked with this new AMA CPT code.” The new CPT code, 0932T, will become effective January 1, 2025.
